Pathological features and clinical behavior of Lynch syndrome-associated ovarian cancer

被引:67
作者
Ryan, N. A. J. [1 ,2 ]
Evans, D. G. [2 ,3 ]
Green, K. [3 ]
Crosbie, E. J. [1 ,4 ]
机构
[1] Univ Manchester, St Marys Hosp, Fac Biol Med & Hlth, Div Mol & Clin Canc Sci, Manchester, Lancs, England
[2] Univ Manchester, St Marys Hosp, Div Evolut & Genom Med, Manchester, Lancs, England
[3] Cent Manchester Univ Hosp, NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Manchester Ctr Genom Med, Manchester, Lancs, England
[4] Cent Manchester Univ Hosp, NHS Fdn Trust, Manchester Acad Hlth Sci Ctr, Dept Obstet & Gynaecol, Manchester, Lancs, England
关键词
GYNECOLOGIC CANCERS; ENDOMETRIAL CANCER; RISK; INDIVIDUALS; MANAGEMENT;
D O I
10.1016/j.ygyno.2017.01.005
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Objective. Lynch syndrome (LS) is an inherited tumor predisposition condition caused by mutations in the mismatch repair (MMR) genes. Mutation carriers are at increased risk of various malignancies, including ovarian cancer (DC). Relatively little is known about the pathological features and clinical behavior of LS associated DC. Methods. We analyzed the data of 1047 proven MMR mutated individuals from a prospectively maintained database at a large referral center for genomic medicine in the North West of England. Data were crosschecked with pathology reports, the National Cancer Registry and death certificates, where appropriate. Data from gynecological surveillance and risk reducing surgery were analyzed. Results. We identified 53 cases of LSAOC in proven MMR mutated individuals. The cumulative risk of LSAOC was 20% at age 80 in those who retained their ovaries. LSAOC presented at an earlier age (average 51, range 2470 years) than sporadic OC. The predominant histological subtype was endometrioid adenocarcinoma (53%). Most cases presented early (85% at stage I/II vs. 15% at stage III/IV, p < 0.001) and overall survival was excellent (80% 5-year survival), however, patients with advanced disease had a poor prognosis (40% 5-year survival). Most women were found to have LS after their OC diagnosis, however, two were detected at Stage lc through gynecological surveillance and a further three were detected following surgery for screen-detected synchronous endometrial pathology. Conclusion. The predominance of early stage disease in LSAOC is linked to its good prognosis. We support risk reducing surgery for women whose families are complete especially if undertaking hysterectomy for endometrial risk, and ovarian surveillance as part of gynecological screening for those who have not. (C) 2017 The Authors. Published by Elsevier Inc.
引用
收藏
页码:491 / 495
页数:5
相关论文
共 24 条
[1]  
Auranen A., 2001, ACTA OBSTET GYNECOL, V90, P437
[2]   Cumulative lifetime incidence of extracolonic cancers in Lynch syndrome: a report of 121 families with proven mutations [J].
Barrow, E. ;
Robinson, L. ;
Alduaij, W. ;
Shenton, A. ;
Clancy, T. ;
Lalloo, F. ;
Hill, J. ;
Evans, D. G. .
CLINICAL GENETICS, 2009, 75 (02) :141-149
[3]   Cancer risk in Lynch Syndrome [J].
Barrow, Emma ;
Hill, James ;
Evans, D. Gareth .
FAMILIAL CANCER, 2013, 12 (02) :229-240
[4]   HEREDITARY OVARIAN-CANCER - A CLINICOPATHOLOGICAL STUDY [J].
BEWTRA, C ;
WATSON, P ;
CONWAY, T ;
READHIPPEE, C ;
LYNCH, HT .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL PATHOLOGY, 1992, 11 (03) :180-187
[5]   Cancer Risks Associated With Germline Mutations in MLH1, MSH2, and MSH6 Genes in Lynch Syndrome [J].
Bonadona, Valerie ;
Bonaiti, Bernard ;
Olschwang, Sylviane ;
Grandjouan, Sophie ;
Huiart, Laetitia ;
Longy, Michel ;
Guimbaud, Rosine ;
Buecher, Bruno ;
Bignon, Yves-Jean ;
Caron, Olivier ;
Colas, Chrystelle ;
Nogues, Catherine ;
Lejeune-Dumoulin, Sophie ;
Olivier-Faivre, Laurence ;
Polycarpe-Osaer, Florence ;
Nguyen, Tan Dat ;
Desseigne, Francoise ;
Saurin, Jean-Christophe ;
Berthet, Pascaline ;
Leroux, Dominique ;
Duffour, Jacqueline ;
Manouvrier, Sylvie ;
Frebourg, Thierry ;
Sobol, Hagay ;
Lasset, Christine ;
Bonaiti-Pellie, Catherine .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2011, 305 (22) :2304-2310
[6]   The incidence of Lynch syndrome [J].
de la Chapelle, A .
FAMILIAL CANCER, 2005, 4 (03) :233-237
[7]   Screening for familial ovarian cancer: poor survival of BRCA1/2 related cancers [J].
Evans, D. G. ;
Gaarenstroom, K. N. ;
Stirling, D. ;
Shenton, A. ;
Maehle, L. ;
Dorum, A. ;
Steel, M. ;
Lalloo, F. ;
Apold, J. ;
Porteous, M. E. ;
Vasen, H. F. A. ;
van Asperen, C. J. ;
Moller, P. .
JOURNAL OF MEDICAL GENETICS, 2009, 46 (09) :593-597
[8]   Survival in women with MMR mutations and ovarian cancer: a multicentre study in Lynch syndrome kindreds [J].
Grindedal, Eli Marie ;
Renkonen-Sinisalo, Laura ;
Vasen, Hans ;
Evans, Gareth ;
Sala, Paola ;
Blanco, Ignacio ;
Gronwald, Jacek ;
Apold, Jaran ;
Eccles, Diana M. ;
Alonso Sanchez, Angel ;
Sampson, Julian ;
Jarvinen, Heikki J. ;
Bertario, Lucio ;
Crawford, Gillian C. ;
Stormorken, Astrid Tenden ;
Maehle, Lovise ;
Moller, Pal .
JOURNAL OF MEDICAL GENETICS, 2010, 47 (02) :99-102
[9]   The Search for Unaffected Individuals with Lynch Syndrome: Do the Ends Justify the Means? [J].
Hampel, Heather ;
de la Chapelle, Albert .
CANCER PREVENTION RESEARCH, 2011, 4 (01) :1-5
[10]   Ovarian cancer in Lynch syndrome; a systematic review [J].
Helder-Woolderink, J. M. ;
Blok, E. A. ;
Vasen, H. F. A. ;
Hollema, H. ;
Mourits, M. J. ;
De Bock, G. H. .
EUROPEAN JOURNAL OF CANCER, 2016, 55 :65-73